The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Abstract
BACKGROUND: Current antipsychotics have only a limited effect on 2 core aspects of schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline that has a beneficial effect in various neurologic disorders. Recent findings in animal models and human case reports suggest its potential for the treatment of schizophrenia. These findings may be linked to the effect of minocycline on the glutamatergic system, through inhibition of nitric oxide synthase and blocking of nitric oxide-induced neurotoxicity. Other proposed mechanisms of action include effects of minocycline on the dopaminergic system and its inhibition of microglial activation. OBJECTIVE: To examine the efficacy of minocycline as an add-on treatment for alleviating negative and cognitive symptoms in early-phase schizophrenia. METHOD: A longitudinal double-blind, randomized, placebo-controlled design was used, and patients were followed for 6 months from August 2003 to March 2007. Seventy early-phase schizophrenia patients (according to DSM-IV) were recruited and 54 were randomly allocated in a 2:1 ratio to minocycline 200 mg/d. All patients had been initiated on treatment with an atypical antipsychotic < or = 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/d chlorpromazine-equivalent doses). Clinical, cognitive, and functional assessments were conducted, with the Scale for the Assessment of Negative Symptoms (SANS) as the primary outcome measure. RESULTS: Minocycline was well tolerated, with few adverse events. It showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale). A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning). CONCLUSIONS: Minocycline treatment was associated with improvement in negative symptoms and executive functioning, both related to frontal-lobe activity. Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00733057.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Levkovitz et al., 2010
In the citing paper
“The sole exception was a trial29 that assessed the effects of a 6-month add-on treatment with either minocycline or placebo on cognitive impairment in young subjects in early phase schizophrenia, aged 18–35 years.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Minocycline showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“A trial performed in younger subjects with recent illness onset29 may yield more positive results than those conducted in patients with an average illness duration of >20 years (See table 1).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“add-on administration of minocycline for 22 weeks was associated with improvements in executive functions in individuals with early-phase schizophrenia [107].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [107]
Citations
Cites
Maximum Likelihood from Incomplete Data Via the EM Algorithm
Dempster, A. P., Laird, N. M., & Rubin, D. B. (1977) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1977.tb01600.x · Cited by 50,444
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. (2000) · Cognitive Psychology · doi:10.1006/cogp.1999.0734 · Cited by 15,798
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Negative v Positive Schizophrenia
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,008
Executive Function and the Frontal Lobes: A Meta-Analytic Review
Alvarez, J. A., & Emory, E. (2006) · Neuropsychology Review · doi:10.1007/s11065-006-9002-x · Cited by 1,981
Teoria Statistica Delle Classi e Calcolo Delle Probabilità
(2010) · Sage eBooks · doi:10.4135/9781412961288.n455 · Cited by 1,706
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422
Revising axis V for DSM-IV: a review of measures of social functioning
Goldman, H. H., Skodol, A. E., & Lave, T. R. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1148 · Cited by 1,408
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Executive functions and the frontal lobes: a conceptual view
Stuss, D. T., & Alexander, M. P. (2000) · Psychological Research · doi:10.1007/s004269900007 · Cited by 1,159
Microglia: Intrinsic immuneffector cell of the brain
Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V. O., Li, M., Sarang, S. S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,069
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Adult clinical neuropsychology: lessons from studies of the frontal lobes
Stuss, D. T., & Levine, B. (2002) · Annual Review of Psychology · doi:10.1146/annurev.psych.53.100901.135220 · Cited by 992
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A., Koffel, B., Laporte, D., & Tamminga, C. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 965
Duration of psychosis and outcome in first-episode schizophrenia
Loebel, A. D., Lieberman, J. A., Alvir, J. M., Mayerhoff, D. I., Geisler, S. H., & Szymanski, S. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1183 · Cited by 880
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 858
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Haro, J. M., Kamath, S., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodríguez, M. J., Rele, R., Orta, J., Kharbeng, A., et al. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.107.s416.5.x · Cited by 659
Statistical Considerations in the Intent-to-Treat Principle
Lachin, J. M. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00046-5 · Cited by 652
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Dissociating executive functions of the prefrontal cortex.
Robbins, T. W. (1996) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1996.0131 · Cited by 574
Insight in Schizophrenia. Its Relationship to Acute Psychopathology
McEvoy, J. P., Apperson, L. J., Appelbaum, P. S., Ortlip, P., Brecosky, J., Hammill, K., Geller, J. L., & Roth, L. H. (1989) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198901000-00007 · Cited by 534
Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective
Lieberman, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00147-x · Cited by 486
Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 471
Role of NO Production in NMDA Receptor-Mediated Neurotransmitter Release in Cerebral Cortex
Montague, P. R., Gancayco, C. D., Winn, M. J., Marchase, R. B., & Friedlander, M. J. (1994) · Science · doi:10.1126/science.7508638 · Cited by 466
Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?
Harvey, P. D., Koren, D., Reichenberg, A., & Bowie, C. R. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj011 · Cited by 458
Minocycline treatment in acute stroke
Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A. M., Anca-Hershkowitz, M., & Sadeh, M. (2007) · Neurology · doi:10.1212/01.wnl.0000277487.04281.db · Cited by 452
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 424
Schizophrenia and Glutamatergic Transmission
Tamminga, C. A. (1998) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v12.i1-2.20 · Cited by 382
Peroxynitrite Inhibits Glutamate Transporter Subtypes
Trotti, D., Rossi, D., Gjesdal, O., Levy, L. M., Racagni, G., Danbolt, N. C., & Volterra, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.5976 · Cited by 371
Cognitive function in schizophrenia
Sharma, T., & Antonova, L. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00084-9 · Cited by 367
Clinical Pharmacokinetics of Doxycycline and Minocycline
Saivin, S., & Houin, G. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815060-00001 · Cited by 350
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 327
Álvarez‐Jiménez, M., Hetrick, S. E., González‐Blanch, C., Gleeson, J., & McGorry, P. D. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042853 · Cited by 315
Structural Evaluation of the Prefrontal Cortex in Schizophrenia
Buchanan, R. W., Vladar, K., Barta, P. E., & Pearlson, G. D. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.8.1049 · Cited by 314
Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309
Physiological and Pathophysiological Roles of Nitric Oxide in the Central Nervous System
Szabó, C. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(96)00159-1 · Cited by 295
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia
Abi‐Dargham, A., & Moore, H. M. (2003) · The Neuroscientist · doi:10.1177/1073858403252674 · Cited by 279
Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
Álvarez‐Jiménez, M., González‐Blanch, C., Crespo‐Facorro, B., Hetrick, S. E., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., & Vázquez‐Barquero, J. L. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00002 · Cited by 271
Nitric oxide stimulates Ca2+-independent synaptic vesicle release
Meffert, M. K. (1994) · Neuron · doi:10.1016/0896-6273(94)90440-5 · Cited by 255
Depino, A. M., Earl, C. D., Kaczmarczyk, E., Ferrari, C. C., Besedovsky, H. O., del Rey, A., Pitossi, F. J., & Oertel, W. H. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03014.x · Cited by 237
Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis
Davidson, L. L., & Heinrichs, R. W. (2003) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(02)00118-x · Cited by 232
Interventions to reduce weight gain in schizophrenia
Faulkner, G., Cohn, T. A., & Remington, G. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005148.pub2 · Cited by 226
Wright, I. C., Ellison, Z., Sharma, T., Friston, K. J., Murray, R. M., & McGuire, P. K. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00094-2 · Cited by 219
Safety of long-term high-dose minocycline in the treatment of acne
Goulden, V., GLASS, D., & Cunliffe, W. J. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb06972.x · Cited by 218
The Case of the Missing Data: Methods of Dealing with Dropouts and other Research Vagaries
Streiner, D. L. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700111 · Cited by 215
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.005 · Cited by 209
Neuroprotection by tetracyclines
Domercq, M., & Matute, C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.001 · Cited by 205
Negative symptoms of schizophrenia: a problem that will not go away
Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00947.x · Cited by 195
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Lôo, H., Poirier, M. F., Theron, M., Rein, W., & Fleurot, O. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195
The frontal lobes and neuropsychiatric illness
(1994) · Journal of Neuropsychiatry · doi:10.1176/jnp.6.4.341 · Cited by 194
Treatment of Schizophrenia Negative Symptoms: Future Prospects
Erhart, S. M., Marder, S. R., & Carpenter, W. T. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj055 · Cited by 185
Gadbury, G. L., Coffey, C. S., & Allison, D. B. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00109.x · Cited by 181
Arató, M., Connor, R. O., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178
Neuropsychological and Psychophysiological Correlates of Psychosocial Functioning in Schizophrenia
Brekke, J. S., Raine, A., Ansel, M., Lencz, T., & Bird, L. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.1.19 · Cited by 177
Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB
Levaux, M., Potvin, S., Sepehry, A. A., Sablier, J., Mendrek, A., & Stip, É. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2006.11.004 · Cited by 175
Xu, L., Fagan, S. C., Waller, J. L., Edwards, D. J., Borlongan, C. V., Zheng, J., Hill, W., Feuerstein, G., & Hess, D. C. (2004) · BMC Neurology · doi:10.1186/1471-2377-4-7 · Cited by 172
Synopsis of function and dysfunction of the frontal lobe
Fuster, J. M. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb05983.x · Cited by 172
Weight gain from novel antipsychotic drugs: need for action
Green, A. I., Patel, J. K., Goisman, R. M., Allison, D. B., & Blackburn, G. L. (2000) · General Hospital Psychiatry · doi:10.1016/s0163-8343(00)00081-5 · Cited by 171
Dropout rates in randomised antipsychotic drug trials
Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001) · Psychopharmacology · doi:10.1007/s002130100711 · Cited by 167
Arvanov, V. L., Liang, X., Schwartz, J. E., Grossman, S. D., & Wang, R. Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37013-2 · Cited by 162
Insight and frontal cortical function in schizophrenia: a review.
Shad, M., Tamminga, C., Cullum, M., Haas, G., & Keshavan, M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.006 · Cited by 161
Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M., & Hashimoto, K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.015 · Cited by 159
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Nitric Oxide - Biochemistry, Molecular Biology, and Therapeutic Implications
(1995) · Advances in pharmacology · doi:10.1016/s1054-3589(08)x6047-8 · Cited by 145
Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis
Gordon, P. H., Moore, D. H., Gelinas, D. F., Qualls, C., Meister, M. E., Werner, J., Mendoza, M., Mass, J., Kushner, G., & Miller, R. G. (2004) · Neurology · doi:10.1212/01.wnl.0000125321.92112.7e · Cited by 139
Weight change with atypical antipsychotics in the treatment of schizophrenia
Haddad, P. M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058378 · Cited by 131
Kurtz, M. M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi004 · Cited by 125
Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain
Baptista, T., Fakih, Y. E., Uzcátegui, E., Sandia, I., Tálamo, E., de Baptista, E. A., & Beaulieu, S. (2008) · CNS Drugs · doi:10.2165/00023210-200822060-00003 · Cited by 118
Possible antipsychotic effects of minocycline in patients with schizophrenia
Miyaoka, T., Yasukawa, R., YASUDA, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.08.013 · Cited by 105
Zhang, L., Shirayama, Y., Iyo, M., & Hashimoto, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301313 · Cited by 105
Mazumdar, S., Liu, K. S., Houck, P. R., & Reynolds, C. F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)00058-2 · Cited by 103
Nitric oxide inhibits 3H‐glutamate transport in synaptosomes
Pöğün, Ş., Dawson, V. L., & Kuhar, M. J. (1994) · Synapse · doi:10.1002/syn.890180104 · Cited by 102
COMPARISON OF ALTERNATIVE STRATEGIES FOR ANALYSIS OF LONGITUDINAL TRIALS WITH DROPOUTS
Liu, G. F., & Gould, A. L. (2002) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-120015744 · Cited by 101
Fujita, Y., Ishima, T., Kunitachi, S., Hagiwara, H., Zhang, L., Iyo, M., & Hashimoto, K. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.031 · Cited by 99
Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., & Lancrenon, S. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00887.x · Cited by 95
Schwieler, L., Linderholm, K. R., Nilsson-Todd, L. K., Erhardt, S., & Engberg, G. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.05.014 · Cited by 94
Neuropsychological frontal impairments and negative symptoms in schizophrenia
Martino, D. J., Bucay, D., Butman, J., & Allegri, R. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.03.002 · Cited by 90
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 87
Inhibitory effect of minocycline on amyloid β fibril formation and human microglial activation
Familian, A., Boshuizen, R. S., Eikelenboom, P., & Veerhuis, R. (2005) · Glia · doi:10.1002/glia.20268 · Cited by 86
Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management
Rege, S. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670801961123 · Cited by 78
Levkovitz, Y., Levi, U., Braw, Y., & Cohen, H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.03.080 · Cited by 74
Self-citationDonohoe, G., & Robertson, I. (2003) · Neurocase · doi:10.1076/neur.9.2.97.15075 · Cited by 71
Jiang, S. X., Lertvorachon, J., Hou, S., Konishi, Y., Webster, J., Mealing, G. A. R., Brunette, E., Tauskela, J. S., & Preston, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503113200 · Cited by 70
Cooper, S. J., Tweed, J. A., Raniwalla, J., Butler, A., & Welch, C. P. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101003218.x · Cited by 67
Sequential Memory: A Developmental Perspective on Its Relation to Frontal Lobe Functioning
Romine, C. B., & Reynolds, C. R. (2004) · Neuropsychology Review · doi:10.1023/b:nerv.0000026648.94811.32 · Cited by 67
Hashimoto, K., Tsukada, H., Nishiyama, S., Fukumoto, D., Kakiuchi, T., & Iyo, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.019 · Cited by 65
Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS)
Lançon, C. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00075-0 · Cited by 54
Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation
Song, Y., Wei, E.-Q., Zhang, W.-P., Ge, Q., Liu, J., Wang, M., Huang, X.-J., Hu, X., & Chen, Z. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.042 · Cited by 52
Prurigo pigmentosa successfully treated with minocycline
Miki, A. S. O., Miyamoto, T., MORIMURA, T., & SHIMAO, S. (1989) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1989.tb01360.x · Cited by 47
Possible anti-catatonic effects of minocycline in patients with schizophrenia
Ahuja, N., & Carroll, B. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.018 · Cited by 41
Non-neuroleptic approaches to treating negative symptoms in schizophrenia
M�ller, H.-J. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0503-4 · Cited by 40
Microglial activation in schizophrenia and minocycline treatment
Hashimoto, K. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.06.012 · Cited by 35
Velakoulis, D., & Pantelis, C. (1996) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679609076095 · Cited by 35
Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia
Harvey, P. D., & McClure, M. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00004 · Cited by 31
NMDA receptor participation in control of food intake by the stomach
Covașă, M., Ritter, R. C., & Burns, G. A. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.5.r1362 · Cited by 31
Minocycline for patients with ALS
Leigh, P., Meininger, V., Bensimon, G., Cudkowicz, M., & Robberecht, W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70006-1 · Cited by 30
Revisiting safety of minocycline as neuroprotection in Huntington's disease
Reynolds, N. C. (2006) · Movement Disorders · doi:10.1002/mds.21199 · Cited by 22
Rabinowitz, J., & Davidov, O. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm107 · Cited by 17
Covașă, M., Ritter, R. C., & Burns, G. A. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.2.r345 · Cited by 15
ALS Trial Raises Questions About Promising Drug
Couzin, J. (2007) · Science · doi:10.1126/science.318.5854.1227a · Cited by 13
Cited by
Sorted by citations
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
Calcia, M., Bonsall, D. R., Bloomfield, P. S., Selvaraj, S., Barichello, T., & Howes, O. D. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4218-9 · Cited by 748
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
Metadata
- Authors
- Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S.
- Affiliations
- Shalvata Mental Health Center (IL)
- Corresponding author
- Levkovitz, Yechiel
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-11-03
- Volume
- 71
- Issue
- 02
- Pages
- 138-149
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2084588595
- Cited by
- 387
- References
- 112
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 26 · 2019: 22 · 2018: 26 · 2017: 15 · 2016: 33 · 2015: 42 · 2014: 34 · 2013: 44 · 2012: 27
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- minocycline, early-phase schizophrenia, negative symptoms, cognitive impairment, executive function, adjunctive therapy, glutamatergic system, nitric oxide synthase inhibition, microglial activation, atypical antipsychotics, Scale for the Assessment of Negative Symptoms
- MeSH terms
- Adolescent, Adult, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Minocycline, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
